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Background: Pre-transplant respiratory virus infection has been shown to have negative impact on HCT outcomes even with human rhinoviruses (HRV) alone (Clin Inf Dis 61:192, 2015) ; however, the sample size was too small to separately analyze HRV and human coronaviruses (HCoV), the two most commonly diagnosed respiratory viruses. This study was performed to revisit this question in a large cohort of HCT recipients who had PCR testing for evaluation of respiratory symptoms before HCT. Methods: Adult patients transplanted from 3/2010 to 3/2016 were retrospectively reviewed and grouped into symptomatic patients tested for respiratory virus infection within <90 days prior to transplant, and asymptomatic patients who were not tested. Viruses were categorized into four groups: adenoviruses, RSV, influenza viruses, and human metapneumovirus (HMPV) (group 1); parainfluenza viruses (PIV) 1-4 (group 2); HRV (group 3); and HCoV (group 4). HCT was delayed when feasible for groups 1 and 2 but HCT was not routinely delayed for groups 3 and 4. Transplant outcomes included "days alive and out of hospital" in allograft recipients and overall mortality by day 100 post HCT in all and allograft recipients; endpoints were analyzed using linear and Cox regression models. Results: A total of 1,643 adult HCT recipients were included, of which 946 (58%) were allogeneic HCT recipients.
Of 704 (43%) tested, 307 (44%) had pre-HCT respiratory virus infection. Group 3 viruses were most commonly detected (25%), followed by group 1, group 2, and group 4 (8% vs. 6% vs. 5%). Overall, 6% of all patients died by day 100 with no significant difference between tested and not-tested groups (P = .84). Among allogeneic recipients, 155 had positive detection with a median last positive day prior to HCT of −25 (IQR, −42 to −15); for mortality, 7% (42/564) died in the tested group and 10% (37/382) died in the not-tested group (P = .22). In univariable analyses, pre-HCT respiratory virus infection did not negatively impact mortality in all patients and in the allogeneic HCT subset. Among, allogeneic HCT recipients, pre-HCT respiratory virus infection of individual viral groups also did not show a negative impact on days alive and out of hospital (mean difference to asymptomatic/not-tested patients: PCR positive symptomatic −1.8, 95% CI, −6.1 to 2.5; PCR negative symptomatic −3.2, 95% CI, −6.9 to .5). Results remained non-significant after adjusting for other significant risk factors (stem cell source and conditioning regimen).
Conclusion:
This study suggests that current recommendations to delay HCT for RSV, HMPV, influenza, adenovirus and PIV are effective. The presence of pre-transplant HRV and HCoV, for which delay is not routinely recommended, may not have a negative impact on transplant outcome in adult HCT recipients. Further data are needed to define the relative significance of upper versus lower respiratory tract viral infections.
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